Concomitant use of renin-angiotensin-aldosterone system inhibitors prevent trastuzumab-induced cardiotoxicity in HER2+ breast cancer patients: an institutional retrospective study

Table 1 Risk factors involved in a published clinical risk score for prediction of TIC

Risk Factor	Points
Adjuvant Therapy
Anthracycline chemotherapy	2
Non-anthracycline chemotherapy	2
No identified chemotherapy	0
Age category, years
67 to 74	0
75 to 79	1
80 to 94	2
Cardiovascular conditions and risk factors
Coronary artery disease	2
Atrial fibrillation/flutter	2
Diabetes mellitus	1
Hypertension	1
Renal failure	2

Low risk = 0–3 points, moderate risk = 3–4 points and high risk ≥6 points. Table modified from Ezaz et al., Risk prediction model for heart failure and cardiomyopathy after adjuvant trastuzumab therapy for breast cancer. JAHA 2014:3:e000472

ISSN: 2057-3804